Quantcast
Last updated on April 16, 2014 at 5:49 EDT

Latest Blood disorders Stories

2012-05-10 02:30:48

SUNNYVALE, Calif., May 10, 2012 /PRNewswire/ -- Pharmacyclics, Inc. (Nasdaq: PCYC) today reported financial results and recent developments for its fiscal third quarter ended March 31, 2012. Financial Results for Third Quarter Ended March 31, 2012 The non-GAAP (Generally Accepted Accounting Principles) net loss reported for the fiscal quarter ended March 31, 2012 was $9.3 million, or $0.14 loss per share. This compares with a non-GAAP net loss of $7.4 million, or $0.12 loss per...

2012-05-09 02:25:21

WHITE PLAINS, N.Y., May 9, 2012 /PRNewswire/ -- Actress and singer-songwriter Miranda Cosgrove has been named The Leukemia & Lymphoma Society's National Ambassador for its 2012 Light The Night® Walks and appears in a new public service announcement to promote this important fundraising campaign. "I will walk for my grandmother in hopes of a healthy recovery," said Cosgrove. "I will walk for my fans -- those teens who have battled leukemia -- the most common cancer in teens my age....

2012-05-07 20:20:15

Children's Hospital of Philadelphia researcher finds pathway driving cancer signals Researchers studying the molecular signals that drive a specific type of lymphoma have discovered a key biological pathway leading to this type of cancer. Cancerous cells have been described as being "addicted" to certain oncogenes (cancer-causing genes), and the new research may lay the groundwork for breaking that addiction and effectively treating aggressive types of B cell lymphoma. B cell lymphomas,...

2012-05-07 14:37:05

A new analysis concludes that rituximab, a drug commonly used to treat blood cancers, leads to treatment responses lasting at least five years in approximately one quarter of patients with low platelet counts and a risk of bleeding due to chronic immune thrombocytopenic purpura (ITP). In study results published online today in Blood, the Journal of the American Society of Hematology (ASH), investigators at Weill Cornell Medical College provide the very first long-term outcome data for...

2012-05-07 06:27:04

WASHINGTON, May 7, 2012 /PRNewswire-USNewswire/ -- A new analysis concludes that rituximab, a drug commonly used to treat blood cancers, leads to treatment responses lasting at least five years in approximately one quarter of patients with low platelet counts and a risk of bleeding due to chronic immune thrombocytopenic purpura (ITP). In study results published online today in Blood, the Journal of the American Society of Hematology (ASH), investigators at Weill Cornell Medical...

2012-05-04 06:22:50

CHICAGO, May 4, 2012 /PRNewswire/ -- Data presented today by CSL Behring at the 2012 Thrombosis and Hemostasis Summit of North America (THSNA) showed that a balanced, human 4-factor prothrombin complex concentrate (PCC) is as effective as the current standard of treatment in stopping bleeding in patients receiving vitamin K antagonist therapy (i.e., warfarin). Currently in the United States, fresh frozen plasma is the standard treatment for warfarin reversal. The data are from the first and...

2012-05-04 02:25:12

AMSTERDAM, May 4, 2012 /PRNewswire/ -- - 2nd Invitation to 17th Congress of EHA - European Hematology Association The Board of the European Hematology Association (EHA) has the pleasure to cordially invite you, as a member of the press, to the 17th Congress of EHA. More than 9,000 participants from around the world are expected at the upcoming Congress at the RAI Congress Center in Amsterdam from June 14-17, 2012. About the EHA Annual Congress: The...

2012-04-30 15:54:47

B cell lymphomas are a group of cancers of that originate in lymphoid tissue from B cells, the specialized immune cell type that produces antibodies. The development of B cell lymphoma is associated with several known genetic changes, including increased expression of MYC, a transcription factor that promotes cell growth and division. In this issue of the JCI, Andrei Thomas-Tikhonenko and his colleagues at the University of Pennsylvania in Philadelphia report on their studies to better...

2012-04-30 06:24:26

MONTRÉAL, April 30, 2012 /CNW/ - Canada's most coveted stem cell prize will be awarded to a Stem Cell Network researcher who has used drug screening to find a potential new treatment for a deadly form of cancer. Dr. Aaron Schimmer, associate professor in the University of Toronto's Department of Medical Biophysics and a clinician-scientist in the Princess Margaret Cancer Program/Ontario Cancer Institute at University Health Network, has received the 2012 Till &...

2012-04-26 10:25:39

( ) ( ) ( ) ( ) ( ) ( ) ( ) ( ) DUBLIN and LANGHORNE, Pa., April 26, 2012 /PRNewswire/ -- Jazz Pharmaceuticals plc (Nasdaq: JAZZ) and EUSA Pharma Inc. today announced that the companies have signed a definitive agreement under which Jazz Pharmaceuticals has agreed to acquire EUSA Pharma, a privately-held, specialty pharmaceutical company with headquarters in the United States and United Kingdom, for $650 million in cash(1) and a potential $50 million milestone payable in cash based upon its...